Below are the most recent publications written about "Drug Resistance, Multiple, Bacterial" by people in Profiles.
-
Karlowsky JA, Wise MG, Hackel MA, Six DA, Uehara T, Daigle DM, Pevear DC, Moeck G, Sahm DF. Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22. J Antimicrob Chemother. 2024 12 02; 79(12):3116-3131.
-
Hameed P S, Kotakonda H, Sharma S, Nandishaiah R, Katagihallimath N, Rao R, Sadler C, Slater I, Morton M, Chandrasekaran A, Griffen E, Pillai D, Reddy S, Bharatham N, Venkatesan S, Jonnalagadda V, Jayaraman R, Nanjundappa M, Sharma M, Raveendran S, Rajagopal S, Tumma H, Watters A, Becker H, Lindley J, Flamm R, Huband M, Sahm D, Hackel M, Mathur T, Kolamunnage-Dona R, Unsworth J, Mcentee L, Farrington N, Manickam D, Chandrashekara N, Jayachandiran S, Reddy H, Shanker S, Richard V, Thomas T, Nagaraj S, Datta S, Sambandamurthy V, Ramachandran V, Clay R, Tomayko J, Das S, V B. BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections. Nat Commun. 2024 09 18; 15(1):8202.
-
Marino A, Augello E, Stracquadanio S, Bellanca CM, Cosentino F, Spampinato S, Cantarella G, Bernardini R, Stefani S, Cacopardo B, Nunnari G. Unveiling the Secrets of Acinetobacter baumannii: Resistance, Current Treatments, and Future Innovations. Int J Mol Sci. 2024 Jun 21; 25(13).
-
Khan MAS, Islam Z, Shah ST, Rahman SR. Characterization of biofilm formation and multi-drug resistance among Pseudomonas aeruginosa isolated from hospital wastewater in Dhaka, Bangladesh. J Water Health. 2024 May; 22(5):825-834.
-
Wise MG, Karlowsky JA, Mohamed N, Hermsen ED, Kamat S, Townsend A, Brink A, Soriano A, Paterson DL, Moore LSP, Sahm DF. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022. J Glob Antimicrob Resist. 2024 06; 37:168-175.
-
Mody D, Joshi P, Antil M, Gupta RK, Gupta V. Insights into Kinases of ESKAPE Pathogens for Therapeutic Interventions. Cardiovasc Hematol Agents Med Chem. 2024; 22(3):276-297.
-
Takemura M, Nakamura R, Ota M, Nakai R, Sahm DF, Hackel MA, Yamano Y. In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrob Agents Chemother. 2023 12 14; 67(12):e0034623.
-
Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020. Int J Antimicrob Agents. 2023 May; 61(5):106772.
-
Humphries RM, Janssen H, Hey-Hadavi JH, Hackel M, Sahm D. Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018-2020. Int J Antimicrob Agents. 2023 Feb; 61(2):106724.
-
Kohira N, Hackel MA, Oota M, Takemura M, Hu F, Mizuno H, Sahm DF, Yamano Y. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020. J Glob Antimicrob Resist. 2023 03; 32:181-186.